ZTS vs RMD — Key Metrics
| Metric | ZTS (ZOETIS INC) | RMD (RESMED INC) |
|---|---|---|
| Price | 85.57 | 242.61 |
| Market Cap | 34.77 Billion | 34.12 Billion |
| P/E (TTM) | 14.53 | 22.04 |
| P/B (Quarterly) | 10.101 | 5.438 |
| P/S (TTM) | 3.66 | 5.95 |
| Net Profit Margin (TTM) | 26.1 | 27.8 |
| Gross Margin (TTM) | 71.4 | 61.1 |
| ROE (TTM) | 76.4 | 25.1 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Outperform
Outperform
Recommendation Summary
Stock ZTS is projected to greatly outperform the market, stock RMD is projected to outperform the market. Upfront Recommendation: ZTS.
Financial Metrics
| ZTS | Metrics | RMD |
|---|---|---|
| $85.57 | Price | $242.61 |
| — | Market Capitalization | — |
| 14.53 | Price to Earnings Ratio | 22.04 |
| 3.66 | Price to Sales | 5.95 |
| 15.2 | Price to FCF Ratio | 21.21 |
| 5.13 | Price to Gross Profit | 9.75 |
| 47.89 | Price to R&D | 86.65 |
| 5.52 | Price to Current Assets | 9.73 |
ZTS vs RMD at a glance
Zoetis INC (ZTS) and Resmed INC (RMD) are both in the Healthcare sector. They are similar in size: $34.8 billion and $34.1 billion in market value.
On trailing-twelve-month figures, ZTS trades at 14.5 times trailing earnings and RMD at 22.0; net profit margins are 26.1% and 27.8%.
The Upfront Investment model currently rates ZTS Greatly Outperform and RMD Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.